Xeris Biopharma Holdings, Inc. is a biopharmaceutical company developing and marketing medications for chronic endocrine and neurological conditions. Its approved products include Gvoke, a liquid glucagon formulation for severe low blood sugar episodes; Keveyis, for treating periodic paralysis disorders; and Recorlev, which manages excessive cortisol production in Cushing's syndrome patients. The company is also advancing XP-8121, an experimental once-weekly thyroid hormone injection currently in late-stage clinical testing.

entry readiness 0 · NOT READY · exit proximity 78

Value area 7.37–10.66 · 0% of 120d volume overhead · clean runway